Results 151 to 160 of about 55,815 (216)

Post-Translational Modification Networks in Ferroptosis: Orchestrating Defense, Drug Resistance, and Therapeutic Opportunities in Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Chen J, Li L, Fang S, Zhou H.
europepmc   +1 more source

Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country. [PDF]

PLoS One
Do TX, Nguyen HT, Nguyen PTL, Kieu MTT, Duong TV, Pham VNH.   +5 more
europepmc   +1 more source

Phospho-JNK agonists show promising effects for the treatment of hepatocellular carcinoma. [PDF]

iScience
Kim W, Jin H, Miao P, Ozcan M, Liao X, Li M, Iqbal S, Sebhaoui J, Ashraf S, Belmen B, Turkez H, Boren J, Uhlen M, Shi X, Zhang C, Mardinoglu A.   +15 more
europepmc   +1 more source

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer). [PDF]

Future Oncol
Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Dao TV, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Kurland JF, Balaji K, Abou-Alfa GK.   +23 more
europepmc   +1 more source

Design, synthesis, and <i>in vitro</i> antiproliferative activity of novel 4-amino-6-phenoxyquinoline and 4,6-diphenoxyquinoline. [PDF]

RSC Adv
Al-Sheikh A, Abuoun M, Khalaf H, Albaz N, Zaytoun A, Abuarqoub D.   +5 more
europepmc   +1 more source

Computational-experimental repurposing reveals synergistic sorafenib/hydroxychloroquine response in KRAS-mutant breast cancer. [PDF]

BMC Pharmacol Toxicol
Abdelwahab MM, Soliman M, Nassrallah A.
europepmc   +1 more source

Small Extracellular Vesicle‐Associated Polymeric Immunoglobulin Receptor in Primary Liver Cancer: From Immunological Mediator to Oncogenic Driver and Biomarker

Cell Proliferation, Volume 59, Issue 8, August 2026.
Jeremy Ting Ruei Hsu, Samuel Wan Ki Wong, Judy Yam Wai Ping   +2 more
wiley   +1 more source

Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma. [PDF]

J Gastrointest Oncol
Ono A, Hayes CN, Kawaoka T, Tsuge M, Oka S.   +4 more
europepmc   +1 more source

Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies. [PDF]

MedComm (2020)
He P, Xie S, Xie K, Gao F, Cai Y, Huang Y, Liu C, Wu H, Lyu Y, Lan T.   +9 more
europepmc   +1 more source

Chemotherapy-derived DAMPs drive reprogramming of tumor-associated macrophages toward a pro-inflammatory phenotype in hepatocellular carcinoma. [PDF]

Sci Rep
Songjang W, Paiyabhroma N, Srisuwan C, Promchai S, Nensat C, Pankhong P, Kumphune S, Jiraviriyakul A.   +7 more
europepmc   +1 more source